Relevant bibliographies by topics / Intranasal administration of dopamine

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Intranasal administration of dopamine'

Author: Grafiati
Published: 5 June 2025
Last updated: 16 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Intranasal administration of dopamine.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Intranasal administration of dopamine"

1

Dagda, Ruben K., Raul Y. Dagda, Emmanuel Vazquez-Mayorga, Bridget Martinez, and Aine Gallahue. "Intranasal Administration of Forskolin and Noopept Reverses Parkinsonian Pathology in PINK1 Knockout Rats." International Journal of Molecular Sciences 24, no. 1 (2022): 690. http://dx.doi.org/10.3390/ijms24010690.

Full text
Abstract:
Parkinson’s Disease (PD) is a brain-degenerative disorder characterized by a progressive loss of midbrain dopamine neurons. Current standard-of-care includes oral administration of Levodopa to address motor symptoms, but this treatment is not disease-modifying. A reduction in Protein Kinase A (PKA) signaling and neurotrophic support contributes to PD pathology. We previously showed that enhancing PKA activity in the brain via intraperitoneal administration of Forskolin in Parkinsonian rats (PINK1 knockout) abrogate motor symptoms and loss of midbrain dopamine neurons. Given that intraperitoneal administration is invasive, we hypothesized that intranasal administration of Forskolin and a second nootropic agent (Noopept) could reverse PD pathology efficiently. Results show that intranasal administration of a formulation (CNS/CT-001) containing Forskolin (10 µM) and Noopept (20 nM) significantly reversed motor symptoms, loss of hind limb strength, and neurodegeneration of midbrain dopamine neurons in PINK1-KO rats and is indistinguishable from wild-type (WT) rats; therapeutic effects associated with increased PKA activity and levels of BDNF and NGF in the brain. Intranasal administration of CNS/CT-001, but not Forskolin, significantly decreased the number of α-synuclein aggregates in the cortex of PINK1-KO rats, and is indistinguishable from WT rats. Overall, we show proof of concept that intranasal administration of CNS/CT-001 is a non-invasive, disease-modifying formulation for PD.
APA, Harvard, Vancouver, ISO, and other styles
2

Nedorubov, Andrey Anatolievich, Alexey Nikitich Pavlov, Natalia Valeryevna Pyatigorskaya, Galina Eduardovna Brkich, and Marina Maksimovna Shabalina. "Pharmacokinetics of Nanosomal Form of Levodopa in Intranasal Administration." Open Access Macedonian Journal of Medical Sciences 7, no. 21 (2019): 3509–13. http://dx.doi.org/10.3889/oamjms.2019.749.

Full text
Abstract:
BACKGROUND: Parkinson's disease is one of the most common neurological diseases. Pathogenesis of the disease is associated with destruction and death of neurons that produce the neurotransmitter dopamine. The precursor to dopamine, which crosses the protective blood-brain barrier, is the amino acid 3, 4-dihydroxy-L-phenylalanine – levodopa, L-DOPA. The investigational drug is a pharmaceutical composition, containing L-DOPA as an active substance, which is distributed in a polymer matrix based on a biodegradable copolymer of lactic/glycolic acids.
 AIM: This work aimed to study the main pharmacokinetic parameters for the drug "L-DOPA – PC, nasal drops" and comparator drugs "L-DOPA in oil", "L-DOPA – PC in purified water", reference product – tablets "Madopar 125".
 METHODS: To increase the bioavailability of the active substance L-DOPA, a new route of administration was used for the first time – nasal administration. Pharmacokinetics of the innovative drug with the intranasal route of administration was investigated in rabbits. The L-DOPA concentration in blood plasma was determined by high-performance liquid chromatography with tandem mass spectrometry (HPLC-MS/MS).
 RESULTS: Bioavailability of the drug – nasal drops were 244.4% compared with the drug "Madopar 125".
 CONCLUSION: Assay procedure for the determination of L-DOPA in animal blood plasma using liquid chromatography with tandem mass-selective detection (HPLC-MS/MS) was developed and validated.
APA, Harvard, Vancouver, ISO, and other styles
3

Amikishieva, A., and A. Cholodar. "P.1.c.066 Behavioural effects of intranasal dopamine administration." European Neuropsychopharmacology 20 (August 2010): S273. http://dx.doi.org/10.1016/s0924-977x(10)70353-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Cox, Sylvia M. L., Chawki Benkelfat, Alain Dagher, et al. "Striatal Dopamine Responses to Intranasal Cocaine Self-Administration in Humans." Biological Psychiatry 65, no. 10 (2009): 846–50. http://dx.doi.org/10.1016/j.biopsych.2009.01.021.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Levicheva, N. O., O. G. Berchenko, and Y. Y. Ilina. "Effect of Intranasal Administration of Dopamine on Odor Perception in Rats with Nigrostriatal Dysfunction." Ukraïnsʹkij žurnal medicini, bìologìï ta sportu 6, no. 3 (2021): 333–39. http://dx.doi.org/10.26693/jmbs06.03.333.

Full text
Abstract:
In recent years, there has been a growing interest in finding early predictors of Parkinson’s disease. In this regard, it is worth noting the olfactory dysfunction, which is associated with the death of neurons in the structures of the limbic system of the brain and a decrease in dopamine levels in the striatum. It was found that most patients with Parkinson’s disease have a clear olfactory dysfunction in the form of impaired differentiation and identification of odors. It has been suggested that the use of low doses of dopamine in the early stages of Parkinson’s disease will stop the progression of central nervous system disorders. The purpose of the study was to investigate the effect of intranasal administration of small doses of dopamine on the early manifestations of fine motor skills and olfactory sensory system function in nigrostriatal dysfunction in rats. Materials and methods. The experiments were performed on 2 groups of animals (n=14) with nigrostriatal dysfunction, which was modulated by partial bilateral electrical damage to the compact part of the substantia nigra. Stereotactic coordinates of the substantia nigra area were determined from the brain maps of rats by Fifkova and Marshall (quoted by Buresh), which corresponded to the distance from the point of intersection of the sagittal suture with bregma: F=5.5 mm, L=1.7 mm, H=9.0 mm. Rats of the first group (n=8) were intranasally administered with small doses of dopamine, and rats of the second group (n=6) were a comparison group. The fine motor skills of the forelimbs and the functional state of the olfactory system were studied when rats were presented with different odorants: emotionally positive (isovaleric acid) and emotionally negative (lemon essential oil) odorants. Results and discussion. The dynamics of the development of nigrostriatal dysfunction revealed a decrease in coordinated motor activity of the forelimbs, muscles of the oral pole and tongue and increased olfactory sensitivity to emotionally negative odorant (lemon essential oil) and loss of 40% of animals’ olfactory sensitivity to emotionally positive isovaleric odor. Conclusion. Prolonged intranasal administration of low doses of dopamine for 10 days to rats with nigrostriatal dysfunction resulted in a 26.2% increase in the activity of fine motor skills of the forelimbs, oral poles and tongue. In these rats, recovery of olfactory sensitivity to the perception of the smell of emotionally negative odorant was found. The action of the emotionally positive stimulus of isovaleric acid revealed an increase in olfactory sensitivity in 75% of animals to the level of baseline values and a decrease in the threshold of sensitivity to it, which was reflected in an increase in the number of approaches and time of odorant research
APA, Harvard, Vancouver, ISO, and other styles
6

Mizutani, Asuka, Masato Kobayashi, Makoto Ohuchi, et al. "Indirect SPECT Imaging Evaluation for Possible Nose-to-Brain Drug Delivery Using a Compound with Poor Blood–Brain Barrier Permeability in Mice." Pharmaceutics 14, no. 5 (2022): 1026. http://dx.doi.org/10.3390/pharmaceutics14051026.

Full text
Abstract:
Single-photon emission computed tomography (SPECT) imaging using intravenous radioactive ligand administration to indirectly evaluate the time-dependent effect of intranasal drugs with poor blood-brain barrier permeability on brain drug distributions in mice was evaluated. The biodistribution was examined using domperidone, a dopamine D2 receptor ligand, as the model drug, with intranasal administration at 0, 15, or 30 min before intravenous [123I]IBZM administration. In the striatum, [123I]IBZM accumulation was significantly lower after intranasal (IN) domperidone administration than in controls 15 min after intravenous [125I]IBZM administration. [123I]IBZM SPECT was acquired with intravenous (IV) or IN domperidone administration 15 min before [123I]IBZM, and time–activity curves were obtained. In the striatum, [123I]IBZM accumulation was clearly lower in the IN group than in the control and IV groups. Time–activity curves showed no significant difference between the control and IV groups in the striatum, and values were significantly lowest during the first 10 min in the IN group. In the IN group, binding potential and % of receptor occupancy were significantly lower and higher, respectively, compared to the control and IV groups. Thus, brain-migrated domperidone inhibited D2R binding of [123I]IBZM. SPECT imaging is suitable for research to indirectly explore nose-to-brain drug delivery and locus-specific biological distribution.
APA, Harvard, Vancouver, ISO, and other styles
7

Sergeyeva, T. N., and K. S. Sergeyeva. "EFFECTS OF INTRANASAL BACTERIAL ENDOTOXIN ADMINISTRATION ON EXPRESSION OF ALPHA-SYNUCLEIN IN PERIPHERAL STRUCTURES OF THE OLFACTORY SYSTEM." Medical academic journal 19, no. 1S (2019): 103–4. http://dx.doi.org/10.17816/maj191s1103-104.

Full text
Abstract:
The involvement of olfactory dysfunction led to the proposal of ‘the olfactory vector hypothesis’ to explain both olfactory losses and the etiology of idiopathic Parkinson disease (PD) as a result of the transit of an environmental virus or chemical agent that enters the central nervous system (CNS) via the nose, activating the glial response of the brain that may lead to dopamine neuronal damage. Previously created chronic, progressive a mouse model of PD by intranasal instillation of a LPS displayed several key features of early-stage PD: a progressive hypokinesia, selective loss of dopamine neurons, a reduction in striatal dopamine content, and α-synuclein (α-syn) accumulation and aggregation in the substance nigra. Other PD model based on nasal inoculation with α-syn aggregates also expressed parkinsonian-like behavioral and immunological features.We suggested that intranasal administration of LPS might cause an increase in expression and misfolding of a-syn in olfactory receptor cells that are projected into olfactory bulbs. We observed an increase in the expression of the native and phosphorylated forms of immunoreactive a-syn in olfactory cells, olfactory nerve and olfactory bulbs where, in addition, activated glial cells were observed. The findings suggest that bacterial antigens can cause parkinsonian-like features both by inducing a glial neuroinflammatory response and by increasing the production of phosphorylated a-syn in peripheral structures of the olfactory system.
APA, Harvard, Vancouver, ISO, and other styles
8

Geiko, Valentina, and Olga Berchenko. "Correction of the wake-sleep cycle by intranasal administration of dopamine in modeling of the preclinical stage of Parkinson's disease in rats." EUREKA: Life Sciences, no. 5 (November 16, 2022): 47–57. https://doi.org/10.21303/2504-5695.2022.002643.

Full text
Abstract:
Sleep disorders, which are among the earliest and most sensitive non-motor manifestations of Parkinson's disease (PD), are not diagnosed in 40–50 % of patients and are not subject to the necessary correction. In this regard, the ineffectiveness of a late start of treatment, when more than 50 % of dopamine-producing neurons are already affected, dictates the need to search for and develop approaches to the prevention and slowdown of neurodegenerative pathology at the preclinical stages of its development using adequate experimental models. Taking into account the low bioavailability of dopamine (DA) and data on the advantages of the intranasal route of administration in comparison with oral and parenteral methods of drug delivery to the CNS, the aim of the work was to study the neurophysiological features of the wake-sleep cycle as early manifestations of nigrostriatal insufficiency and the effect of intranasal administration of DA on the quality of sleep during the formation of the preclinical stage of PD in rats. It was shown that under the conditions of modeling PD, the cyclic organization of sleep with a predominance of incomplete cycles against the background of hyperproduction of slow-wave sleep and REM phases are early manifestations of nigrostriatal insufficiency. Course administration of DA at a dose of 3 mg/kg is accompanied by the normalization of sleep quality in the form of reduction (by 76 %) in the number of incomplete cycles. The preventive orientation of the obtained effects may indicate a certain therapeutic potential of intranasal delivery of DA to the brain, aimed at slowing down the processes of neurodegeneration and possibly delaying its clinical manifestation
APA, Harvard, Vancouver, ISO, and other styles
9

Geiko, Valentina, and Olga Berchenko. "Correction of the wake-sleep cycle by intranasal administration of dopamine in modeling of the preclinical stage of Parkinson's disease in rats." EUREKA: Life Sciences, no. 5 (November 16, 2022): 47–57. http://dx.doi.org/10.21303/2504-5695.2022.002643.

Full text
Abstract:
Sleep disorders, which are among the earliest and most sensitive non-motor manifestations of Parkinson's disease (PD), are not diagnosed in 40–50 % of patients and are not subject to the necessary correction. In this regard, the ineffectiveness of a late start of treatment, when more than 50 % of dopamine-producing neurons are already affected, dictates the need to search for and develop approaches to the prevention and slowdown of neurodegenerative pathology at the preclinical stages of its development using adequate experimental models. Taking into account the low bioavailability of dopamine (DA) and data on the advantages of the intranasal route of administration in comparison with oral and parenteral methods of drug delivery to the CNS, the aim of the work was to study the neurophysiological features of the wake-sleep cycle as early manifestations of nigrostriatal insufficiency and the effect of intranasal administration of DA on the quality of sleep during the formation of the preclinical stage of PD in rats. It was shown that under the conditions of modeling PD, the cyclic organization of sleep with a predominance of incomplete cycles against the background of hyperproduction of slow-wave sleep and REM phases are early manifestations of nigrostriatal insufficiency. Course administration of DA at a dose of 3 mg/kg is accompanied by the normalization of sleep quality in the form of reduction (by 76 %) in the number of incomplete cycles. The preventive orientation of the obtained effects may indicate a certain therapeutic potential of intranasal delivery of DA to the brain, aimed at slowing down the processes of neurodegeneration and possibly delaying its clinical manifestation
APA, Harvard, Vancouver, ISO, and other styles
10

Lao, Chu Lan, Yen-Hsi Kuo, Yueh-Ting Hsieh, and Jin-Chung Chen. "Intranasal and Subcutaneous Administration of Dopamine D3 Receptor Agonists Functionally Restores Nigrostriatal Dopamine in MPTP-Treated Mice." Neurotoxicity Research 24, no. 4 (2013): 523–31. http://dx.doi.org/10.1007/s12640-013-9408-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Intranasal administration of dopamine"

1

Jansson, Björn. "Models for the Transfer of Drugs from the Nasal Cavity to the Central Nervous System." Doctoral thesis, Uppsala University, Department of Pharmacy, 2004. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3905.

Full text
Abstract:
<p>The blood-brain barrier restricts the access of many compounds, including therapeutic agents, to the brain. Several human studies indicate that nasal administration of hydrophilic compounds, such as peptides, can bypass the blood-brain barrier. The aims of this thesis were to develop and refine models for this direct nose-to-brain transfer.</p><p>In a mouse model, [<sup>3</sup>H]-dopamine was given as a unilateral nasal dose. The resulting radioactivity in the ipsilateral olfactory bulb was significantly higher than that in the contralateral bulb and peaked at 4 h. Tape section autoradiography showed that the radioactivity was concentrated in the olfactory nerve layer and the glomerular layer of the olfactory bulb. The olfactory transfer of dopamine was also studied <i>in vitro</i>. At a lower donor concentration, the mucosal-to-serosal dopamine permeability was higher than the serosal-to-mucosal permeability, but at a higher concentration, the permeability coefficients were similar. Together, these results suggest that the olfactory transfer of dopamine has an active component.</p><p>Olfactory transfer of fluorescein-labeled dextran through the epithelium and deeper tissues was studied in a rat model, which enabled visualization of the transfer using fluorescence microscopy. Although the epithelial transfer appeared to be mainly intracellular, transfer in the following deeper tissues was extracellular. Without altering the route of uptake, a gellan gum formulation enhanced the uptake of fluorescein dextran. The enhancing effect was considered likely to be the result of an increased residence time in the nasal cavity.</p><p>In conclusion, dopamine and fluorescein-labeled dextran were identified as suitable model compounds for the study of olfactory drug transfer mechanisms and the influence of drug formulation. Two new <i>in vitro</i> models of olfactory transfer were compared. Also, a rat model, which enabled the visualization of the entire nose-to-brain transfer, was developed.</p>
APA, Harvard, Vancouver, ISO, and other styles
2

Charlton, Stuart Thomas. "Drug delivery to the brain via intranasal administration." Thesis, University of Nottingham, 2003. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.275962.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Metzler, Barbara. "Downregulation of systemic immune responses by oral and intranasal antigen administration." Thesis, University of Cambridge, 1994. https://www.repository.cam.ac.uk/handle/1810/270425.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bernocchi, Beatrice. "Porous maltodextrin nanoparticles for the intranasal delivery of vaccines." Thesis, Lille 2, 2016. http://www.theses.fr/2016LIL2S010/document.

Full text
Abstract:
Au cours des dernières décennies, la technologie des nanoparticules pour la délivrance des vaccins au niveau de muqueuses a reçu un intérêt croissant. L’administration intranasale possède de grands avantages pour la stimulation du système immunitaire, telles que la stimulation d’une immunité protectrice locale et systémique. Cependant des systèmes de délivrance et des adjuvants sont souvent nécessaires pour déclencher efficacement la réponse immunitaire. Nous avons appliqué la technologie des nanoparticules en tant que système de délivrance d'un vaccin universel nasal contre la grippe dans un projet européen FP7 appelé UniVacFlu. Nous avons formulé un antigène adjuvé CTA1-3M2e-DD avec les NPL. Cet antigène est composé de la sous-unité A1 de la toxine du choléra et d’un épitope conservé du virus de la grippe A (M2e), ainsi que du dimère de l’analogue synthétique de la protéine A de Staphylococcus aureus (DD). Les nanoparticules utilisées sont poreuses et constituées de maltodextrines réticulées ayant un coeur lipidique (NPL). L’association de cet antigène avec les NPL est quantitative et la formulation est stable pendant au moins six mois à 4°C. Les NPL permettent également de délivrer d’une manière accrue cet antigène dans les cellules épithéliales des voies respiratoires et les macrophages. Actuellement ces formulations sont évaluées chez la souris par le consortium UniVacFlu.L'un des principaux problèmes des vaccins nasal est la toxicité qui peut être provoquée par le passage nez-cerveau de l'un de ses composants. Le but de ce travail est d'évaluer le potentiel des NPL, en tant que vecteurs pour la délivrance des vaccins nasal. Ainsi, nous avons étudié le chargement d’un antigène dans les NPL et sa délivrance dans les cellules épithéliales des voies respiratoires. Notre étude révèle que les NPL interagissent fortement avec les muqueuses et délivrent d’une manière accrue les antigènes dans les cellules. Nous avons également montré l'absence de transcytose et de passage paracellulaire des NPL ou des antigènes délivrés dans un modèle de barrière épithéliale in vitro. Les résultats in vivo confirment l'absence de passage nez-cerveau des NPL et montrent qu’elles prolongent fortement le temps de résidence nasale des antigènes qui sont ensuite éliminés par le tractus gastro-intestinal.Ces résultats mettent en évidence l'intérêt des NPL comme vecteurs pour la prochaine génération de médicaments et de vaccins<br>Nanoparticles technology for mucosal delivery of vaccines received a growing interest in the last decades. Intranasal administration owns great advantages for immune system stimulation, such as local and systemic protection against infectious diseases. However delivery systems and adjuvants are often required to efficiently trigger mucosal and systemic immune responses. In this thesis, nanoparticles (NP) have been evaluated as delivery system for a nasal universal influenza vaccine in a People Program of the European Union Seventh Framework Program FP7 called UniVacFlu. The aim of the UniVacFlu network is to develop a universal influenza vaccine administered through the mucosal route. We used porous maltodextrin nanoparticles with a lipidic core (NPL). We loaded an adjuvanted antigen named CTA1-3M2e-DD in the NPL. CTA1-3M2e-DD is composed of the A1 subunit of the cholera toxin and a conserved epitope of influenza A virus (M2e), while DD, dimer of the synthetic analogue of the Staphyloccous aureus protein A, targets B cells. Interestingly the antigen loading in NPL was quantitative for the antigen: NPL 1:5 mass ratio and the formulation was stable for at least six months at 4°C. We assessed the successful delivery of the antigen by NPL in airway epithelial cells and macrophages. These formulations are currently evaluated by the UniVacFlu consortium in mice.One of the main issues of intranasal vaccines is the toxicity that can be elicited by the nose-brain passage of one of their components. We investigated the loading of antigens in NPL and their delivery in airway mucosa. We observed a high endocytosis of NPL and an increased protein delivery into the cells. On a transwell model of the airway mucosa we assessed the absence of transcytosis and paracellular passage of the NPL. In vivo results confirmed the lack of nose-brain passage of the NPL, as NPL were found not to cross the mucosa. Interestingly, we observed an increased nasal residence time of the protein targeted by NPL. The particles after having delivered their payload are totally eliminated through the gastrointestinal tract, making these nanoparticles good candidates for mucosal delivery system. These results highlight the interest of NPL as vectors for mucosal delivery of drugs
APA, Harvard, Vancouver, ISO, and other styles
5

Pinheiro, Sabrina dos Santos. "Cetamina intranasal para sedoanalgesia na punção venosaperiférica em pacientes pediátricos : estudo randomizado, duplo cego e placebo controlado." reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2016. http://hdl.handle.net/10183/158232.

Full text
Abstract:
Objetivos: Verificar eficácia da cetamina intranasal na sedação de crianças para punção venosa. Métodos: Estudo randomizado, duplo-cego, placebo controlado realizado no Hospital de Clínicas de Porto Alegre entre janeiro e agosto de 2016. Estudo aprovado pela comissão de ética em pesquisa da instituição. Incluídas crianças que necessitasse de punção venosa, sendo randomizadas a receber cetamina IN 4mg/Kg ou solução fisiológica no grupo Placebo. Os grupos foram comparados quanto: tempo de punção, facilidade do Enfermeiro para realizar o procedimento, eventos adversos, alterações dos sinais vitais e percepção do acompanhante. Resultados: Foram incluídas 39 crianças (21 Intervenção vs 18 Placebo) sem diferenças quanto à idade, sexo, peso, motivo da internação e experiência profissional. A mediana da idade foi 19,8 vs 15,8 meses (Intervenção vs. Placebo) e a do peso foi 10 vs. 11,3Kg. A Cetamina reduziu o tempo de punção (23,0 vs 67,5 segundos; p=0,01), deu maior facilidade ao Enfermeiro para realizar o procedimento (p=0,00009). A cetamina induziu uma maior sonolência 15 minutos após (p=0,003) e reduziu o número de pessoas para contenção da criança (p=0,025). Sem diferença entre os grupos nas alterações dos sinais vitais e eventos adversos. Evento adverso observou-se em 29% das crianças do grupo cetamina e 17% do grupo placebo, sendo irritabilidade o mais comum em ambos. Em 81% do grupo Intervenção, o acompanhante afirmou que a criança ficou mais calma (p=0,0003). Conclusões: Cetamina intranasal (4mg/Kg) reduz o tempo de punção venosa, facilitando o procedimento para o enfermeiro, diminuindo o número de pessoas envolvidas e permitindo um ambiente tranquilo.<br>Objectives: To verify the efficacy of intranasal ketamine as sedative agent for venous access in children. Method: Randomized, double blind, placebo controlled study conducted at Hospital de Clínicas de Porto Alegre (Brazil) between January and August 2016. Children needing venous access were randomized to receive intranasal ketamine (4mg/Kg) or normal saline solution (Placebo group). Groups were compared regarding the time for venous access, facility for performing the procedure, adverse events, disturbances in vital signs and perception of the accompanying adult. The study was approved by the Local Ethics Committee. Results: 39 children (21 Ketamine; 18 Placebo) were included without differences regarding to age, sex, weight, reason for hospitalization and professional experience. The median age was similar (19.8 vs 15.8 months), as well as the median weight (10.0 vs 11.3Kg). Ketamine reduced the length for venous access (23.0 vs 67.5 seconds; p=0.01), and facilitated the procedure (p=0.00009). Ketamine induced sleepiness 15 minutes after its administration (p=0.003) and reduced the number of people for the child’s restraint (p=0.025). No difference was verified between groups regarding adverse effects or vital signs disturbance´s. Side effects were observed in 29% of the children in the Ketamine group and 17% in the Placebo group, irritability being the most common for both. The accompanying adult reported that 81% of children in ketamine group were calm and quiet (p=0.0003). Conclusions: Intranasal ketamine (4mg/Kg) reduces the time for venous puncture, facilitates the procedure to the nurse, decreases the number of people involved and provides a tranquil environment.
APA, Harvard, Vancouver, ISO, and other styles
6

Korhonen, Jessica, Modin Håkan, and Alexander Jönsson. "Effekter av intranasalt Fentanyl i prehospital akutsjukvård." Thesis, Högskolan i Halmstad, Sektionen för hälsa och samhälle (HOS), 2014. http://urn.kb.se/resolve?urn=urn:nbn:se:hh:diva-24398.

Full text
Abstract:
Akut smärta är det vanligast förekommande symtom som den prehospitala akutsjukvården ställs inför. Behandlingsriktlinjerna presenterar intranasalt Fentanyl som ett alternativ för akut smärtlindring. Då det finns ett begränsat utbud av studier utförda på vuxna och inom prehospital akutsjukvård var syftet med studien att beskriva effekter av intranasal administrering av Fentanyl i prehospital akutsjukvård. Studien genomfördes med en kvantitativ metod och med en retrospektiv, deskriptiv design. Studien baserades på en granskning av 15 patientjournaler från Ambulanssjukvården i Region Halland och deras journalsystem Paratus. Journaler som inkluderades var de där Fentanyl administrerat. Resultatet visar att en majoritet av patienterna i studien drabbats av muskeloskeletal smärta. Resultatet visade på dokumentationsbrister i granskade patientjournaler. Vidare forskning av Fentanyl i den prehospitala akutsjukvården samt översyn av följsamhet till dokumentationsrutiner är nödvändig.<br>Acute pain is the most common symptom in the prehospital emergency care. The treatment guideline presents Fentanyl as an alternative for treating acute pain. As there is a limited range of studies conducted in adults and in prehospital emergency care the purpose of the study was to illustrate the effects of intranasal administration of Fentanyl in the prehospital emergency care. The study was conducted by a quantitative method and with a retrospective, descriptive design. The study was based on a review of patient records from the Ambulance Service in the Region of Halland and their record system Paratus. Fifteen patient records were Fentanyl was administrated were included in the study. The result showed that a majority of the patients included in the study suffered from musculoskeletal pain. The result showed a lack of documentation in the reviewed records. Further studies and an overview of the compliance of the routines for documentation as well are necessary.
APA, Harvard, Vancouver, ISO, and other styles
7

Skragge, Michael. "Absorption predicts mysticism and spirituality, but not following intranasal oxytocin administration : A sensory deprivation experiment." Thesis, Stockholms universitet, Psykologiska institutionen, 2017. http://urn.kb.se/resolve?urn=urn:nbn:se:su:diva-149613.

Full text
Abstract:
Recent research has indicated a causal link between oxytocin and spirituality. The present experiment sought to examine the effects of intranasal oxytocin (IN-OT) and absorption on mysticism and spirituality in a sensory deprivation setting. The results failed to find any main effects of IN-OT on mysticism, or on spirituality. Interaction effects were discovered however, where IN-OT interacted with absorption both on mysticism and spirituality. More specifically IN-OT undermined the association between absorption and outcomes that were observed in the placebo control condition. The results contradict the findings from the only previous experiment conducted on IN-OT and spirituality. The interaction effects align with previous research on IN-OT, suggesting an increase in suggestibility among low absorption scorers. These results motivate further research on the relation between oxytocin, absorption and spirituality, keeping the idea of suggestibility in mind.
APA, Harvard, Vancouver, ISO, and other styles
8

Filho, Eduardo Mekitarian. "Utilização do midazolam intranasal como sedativo para tomografia em crianças." Universidade de São Paulo, 2013. http://www.teses.usp.br/teses/disponiveis/5/5141/tde-20052013-154238/.

Full text
Abstract:
Objetivos: Avaliar a segurança e a eficácia do midazolam intranasal (MIN) para sedação para tomografia em crianças, bem como a qualidade dos estudos radiológicos obtidos com esta técnica. Material e métodos: Entre dezembro de 2011 e julho de 2012, este estudo prospectivo avaliou o MIN como sedativo para crianças submetidas à tomografia sem acesso venoso. Após aprovação do Comitê de Ética em Pesquisa e consentimento dos responsáveis, 0,4 mg/kg de MIN foi administrado, sendo feita dose adicional de 0,1 mg/kg se o nível de sedação avaliado pela Escala de Sedação de Ramsay não fosse atingida após 15 minutos da primeira dose. Os desfechos relacionados à sedação incluíram tempo para sedação e para atingir os critérios de alta; parâmetros fisiológicos como oximetria de pulso e frequência cardíaca foram registrados a cada cinco minutos até a alta. A qualidade dos exames tomográficos foi avaliada quanto à presença de artefatos de imagem e movimento. Resultados: 60 eventos de sedação foram realizados em 58 pacientes. A idade média foi de 15,5 meses, sendo 90,9% dos exames tomográficos de crânio. O tempo médio para sedação foi de 15,2 minutos (5-40) e o tempo médio para atingir os critérios de alta foi de 74,7 minutos. Eventos adversos foram observados em 5 crianças (8,4%), incluindo reação paradoxal (3), tempo de recuperação prolongado (1) e vômitos (1). Apenas 4 pacientes (6,7%) não foram adequadamente sedados com MIN. Imagens consideradas excelentes, sem artefatos, foram obtidas em 56 (93,3%) sedações. Não houve eventos como bradicardia, hipoxemia ou hipotensão. Conclusões: O midazolam intranasal, administrado via atomizador nasal, é um método simples e não-invasivo para sedação segura, eficaz e previsível para crianças na obtenção de estudos tomográficos de qualidade<br>Objective: To evaluate the safety, efficacy and image quality of sedation with aerosolized intranasal midazolam for pediatric CT studies. Materials and Methods: Between December 2011 to May 2012, this prospective study evaluated aerosolized intranasal (AIN) midazolam as a sedative for CT of children without intravenous access. After IRB approval and parental consent, 0,4 mg/kg of AIN midazolam was administered, and repeated with 0.1 mg/kg if adequate sedation evaluated by Ramsay Sedation Scale not achieved in 15 minutes after the first dose. Sedation outcome variables which included time to achieve sedation, to meet discharge criteria and physiological vital signs of pulse oximetry and heart rate, were recorded every five minutes until discharge. The quality of CT images was reviewed and graded for presence of motion and imaging artifacts, Results: 60 sedation encounters were performed in 58 children. Mean age was 15.5 months, and 90.9% of CT scans were brain scans. Mean time to sedation was 15.2 minutes (range 5-40) and mean time to achieve discharge criteria was 74.7 minutes. Adverse events were recorded in 5 children (8.4%) that underwent sedation - paradoxical reaction (3), prolonged recovery time (1) and vomiting (1). Only 4 patients (6.7%) failed to sedate. Excellent CT imaging, with no artifacts, were obtained in 56 (93.3%) of sedation encounters. No adverse events like bradycardia, hypoxia or hypotension were documented. Conclusions: The aerosolized route of administration of midazolam is a simple and noninvasive approach for predictable, effective and safe sedation of children for quality CT imaging studies
APA, Harvard, Vancouver, ISO, and other styles
9

Thienel-Holzmann, Matthias [Verfasser], and Manfred [Akademischer Betreuer] Hallschmid. "Improving metabolic control in humans by intranasal neuropeptide administration / Matthias Günter Thienel-Holzmann ; Betreuer: Manfred Hallschmid." Tübingen : Universitätsbibliothek Tübingen, 2017. http://d-nb.info/1199546240/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Zanellato, Fabbri Natalia 1981. "Utilização da provocação nasal com histamina e avaliação rinomanometrica em estudos de bioequivalencia para sprays nasais." [s.n.], 2009. http://repositorio.unicamp.br/jspui/handle/REPOSIP/311768.

Full text
Abstract:
Orientador: Ricardo de Lima Zollner<br>Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciencias Medicas<br>Made available in DSpace on 2018-08-14T06:15:03Z (GMT). No. of bitstreams: 1 ZanellatoFabbri_Natalia_M.pdf: 1108663 bytes, checksum: 3362aa87243ab7742f6bb55df1f964e6 (MD5) Previous issue date: 2009<br>Resumo: Rinite alérgica é uma doença comum com ampla morbidade, que gera aumento considerável nos custos de tratamento médico, redução da produtividade no trabalho e absenteísmo escolar. A aplicação tópica de corticosteróides intranasal é amplamente reconhecida como primeira linha de tratamento antiinflamatório. Espera-se que a maioria dos sprays nasais prescritos como drogas de ação local, ainda não possuam patente permitindo o aumento de cópias genéricas desses medicamentos, levando a concorrência e redução de preço. Estudos de bioequivalência para sprays nasais estão ainda em discussão. Geralmente, os estudos para essa finalidade usa modelos de intervenção terapêutica a longo prazo, com altos custos para o paciente e longo tempo de duração. O objetivo deste trabalho foi mostrar a aplicabilidade da provocação nasal com histamina e rinomanometria em estudos de bioequivalência para sprays nasais. Trata-se de um estudo aberto, cruzado aleatorizado, utilizando dois períodos e duas seqüências para avaliar a equivalência farmacodinâmica entre duas formulações de sprays de dipropionato de beclometasona de manufaturamento distinto. Após estímulo nasal com histamina (0,5 mg/ml em ambas narinas), 25 voluntários saudáveis foram submetidos a rinomanometria anterior nos tempos 0; 15; 30 e 60 minutos para estabelecimento do fluxo, pressão e resistência basal de cada câmara nasal. Os voluntários foram submetidos à utilização do spray nasal com a droga teste (T) ou referência (R) de acordo com o esquema de randomização, e a área sobre a curva foi analisada. De acordo com os parâmetros estudados os resultados obtidos mostraram diferença significativa entre as duas formulações (p= 0,31) indicando a equivalência terapêutica entre as drogas T e R. Assim, estes resultados sugerem que provocação nasal com histamina em indivíduos saudáveis e o emprego da rinomanometria como método quantitativo das alterações provocadas nas câmaras nasais possam ser aplicáveis em estudos farmacodinâmicos de bioequivalência para sprays nasais<br>Abstract: Allergic rhinitis is a common condition with widespread morbidity, increased medical treatment costs, reduced work productivity and lost school days. Topically delivered intranasal corticosteroids are widely recognized to be the first-line anti-inflammatory treatment. It is expected that many of the most-prescribed nasal sprays for local action drugs will go off patent, allowing the increase of the generic copies of these medications, with more products competition and price reduction. The bioequivalence studies for nasal sprays are still in discussion. Usually the studies designs for this purpose use a long-term therapeutic intervention models using patients with high costs and time duration. This study was designed to demonstrate the feasibility of rhinomanometry in bioequivalence studies for nasal sprays. Study design, an open, randomized, crossover study, using two periods and two sequences to evaluate pharmacodynamic equivalence between two formulations of beclometasone dipropionate spray. After nasal challenge with histamine (0.5mg/ml, in both nostrils), 25 healthy volunteers were submited to an anterior rhinomanometry at the time 0; 15; 30 and 60 minutes building a baseline of flow, pression and resistance of nasal chamber. Then, the vontuteers were submited to nasal drug spray (Test (T) or Reference(R)), according to randomized schedule and the Are Under Curve (AUC0-t) analyzed. The results suggest the potential use of nasal histamine challenge and rhinomanometry evaluation in healthy subjects in bioequivalence studies for nasal sprays<br>Mestrado<br>Ciencias Basicas<br>Mestre em Clinica Medica
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Intranasal administration of dopamine"

1

1938-, Chien Yie W., ed. Transnasal systemic medications: Fundamentals, developmental concepts, and biomedical assessments. Elsevier, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Dominique, Duchêne, Association de pharmacie galénique industrielle., and Swedish Academy of Pharmaceutical Sciences., eds. Buccal and nasal administration as an alternative to parenteral administration: European symposium, Paris, 10 and 11 December 1991. Editions de Santé., 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

A, Obeso J., and Olanow C. W. 1941-, eds. Beyond the decade of the brain. Wells Medical, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

David, Ganderton, Jones T. M. 1942-, Pharmaceutical Society of Great Britain., and King's College (University of London). Chelsea Dept. of Pharmacy., eds. Drug delivery to the respiratory tract. VCH, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Mamo, David C. The effect of acute antipsychotic administration on dopamine synthesis in rodents and human subjects using 6-[18F]-L-m-tyrosine. National Library of Canada, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

A, Obeso J., Horowski R. 1944-, and Marsden C. David, eds. Continuous dopaminergic stimulation in Parkinson's disease: Proceedings of the workshop in Alicante, Spain, September 22-24, 1986. Springer-Verlag, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ritual enemas and snuffs in the Americas. Centre for Latin American Research and Documentation, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lameire, Norbert. Prevention of acute kidney injury. Edited by Norbert Lameire. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199592548.003.0226_update_001.

Full text
Abstract:
This chapter summarizes the pharmacological interventions that can be used in the prevention of acute kidney injury (AKI). These following interventions are discussed: the use and selection of vasopressors; the administration of loop diuretics and mannitol; vasodilating drugs including dopamine, atrial natriuretic peptide, nesiritide, fenoldopam, and adenosine antagonists. The role of N-acetylcysteine in the prevention of contrast-induced AKI and cardiac surgery is discussed. The chapter concludes with a summary of the potential role of insulin-like growth factor and erythropoietin in the prevention of AKI.
APA, Harvard, Vancouver, ISO, and other styles
9

Thien Lim, Thien, and Hubert H. Fernandez. Parkinson Disease. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199937837.003.0003.

Full text
Abstract:
Levodopa is the most efficacious medication to reduce motor impairment in Parkinson disease (PD). The effect of levodopa can wear off after time, which is treated by increasing the dose or shortening the inter-dose interval. Dyskinesias can be treated by a change in levodopa dosing or route of administration, such as by constant administration of levodopa as a gel through a jejunostomy tube or a change to dopamine agonists or amantadine. Non-motor signs including depression can be treated with several antidepressants. Surgical treatments including pallidotomy, thalamotomy, and deep brain stimulation (DBS) have emerged as effective therapies in selected patients with PD refractory to drug treatment.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Intranasal administration of dopamine"

1

Olsson, P., F. Kuylenstierna, C.-J. Johansson, PO Gunnarsson, and M. Bende. "Pharmacokinetics of Nicotine after Intranasal Administration." In Effects of Nicotine on Biological Systems. Birkhäuser Basel, 1991. http://dx.doi.org/10.1007/978-3-0348-7457-1_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Harris, A. S. "Biopharmaceutical Aspects on the Intranasal Administration of Peptides." In Delivery Systems for Peptide Drugs. Springer US, 1986. http://dx.doi.org/10.1007/978-1-4757-9960-6_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Evgen’ev, Michael B., David G. Garbuz, Alexei V. Morozov, and Natalia V. Bobkova. "Intranasal Administration of Hsp70: Molecular and Therapeutic Consequences." In HSP70 in Human Diseases and Disorders. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-89551-2_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Greenshaw, Andrew J., Glen B. Baker, and Thomas B. Wishart. "Dopamine Receptor Changes During Chronic Drug Administration." In Psychoactive Drugs. Humana Press, 1989. http://dx.doi.org/10.1007/978-1-59259-464-1_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Corrigall, William A. "Regulation of Intravenous Nicotine Self-Administration — Dopamine Mechanisms." In Effects of Nicotine on Biological Systems. Birkhäuser Basel, 1991. http://dx.doi.org/10.1007/978-3-0348-7457-1_56.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kalivas, P. W. "Repeated Administration with Enkephalin into the A-10 Dopamine Region Produces Supersensitivity of the Mesolimbic Dopamine System." In Dopaminergic Systems and their Regulation. Palgrave Macmillan UK, 1986. http://dx.doi.org/10.1007/978-1-349-07431-0_59.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Zahniser, Nancy R., Joanna Peris, Pamela Curella, Linda P. Dwoskin, Laurie O’Keefe, and Sally J. Boyson. "Repeated Cocaine Administration Results in Supersensitive Nigrostriatal D-2 Dopamine Autoreceptors." In Pharmacology and Functional Regulation of Dopaminergic Neurons. Palgrave Macmillan UK, 1988. http://dx.doi.org/10.1007/978-1-349-10047-7_26.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kulkarni, Amod P., Dhirendra Govender, Lauriston A. Kellaway, and Girish J. Kotwal. "Central Nervous System Distribution of the Poxviral Proteins After Intranasal Administration of Proteins and Titering of Vaccinia Virus in the Brain After Intracranial Administration." In Methods in Molecular Biology. Humana Press, 2012. http://dx.doi.org/10.1007/978-1-61779-876-4_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Christensen, A. V., J. Arnt, and O. Svendsen. "Pharmacological Differentiation of Dopamine D-1 and D-2 Antagonists After Single and Repeated Administration." In Dyskinesia. Springer Berlin Heidelberg, 1985. http://dx.doi.org/10.1007/978-3-642-70140-5_22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Dostert, Philippe, Didier Deffond, Renata La Croix, Didier Vernay, Margherita Strolin Benedetti, and Gerard Dordain. "Effect of Selegiline Administration on the Urinary Excretion of Dopamine-Derived Tetrahydroisoquinoline Alkaloids in Parkinson’s Disease Patients." In Alzheimer’s and Parkinson’s Diseases. Springer US, 1995. http://dx.doi.org/10.1007/978-1-4757-9145-7_81.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Intranasal administration of dopamine"

1

Yu-Taeger, Libo, Janice Stricker-Shaver, Katrin Arnold, et al. "I22 Intranasal administration of mesenchymal stem cells ameliorates the abnormal dopamine transmission system and inflammatory reaction in the R6/2 mouse model of huntington disease." In EHDN 2018 Plenary Meeting, Vienna, Austria, Programme and Abstracts. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/jnnp-2018-ehdn.258.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kulkarni, Tanmay, Deepa Gupta, Dan Covey, Joseph Cheer, and Gymama Slaughter. "Dopamine sensing upon amphetamine administration." In 2015 IEEE Sensors. IEEE, 2015. http://dx.doi.org/10.1109/icsens.2015.7370580.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Litvinova, M., E. Bychkov, A. Lebedev, Petr Shabanov, and N. Arseniev. "Estimation of behavioral responses with intranasal administration of 6-OHDA." In II Международная конференция, посвящеенная 100- летию И.А. Држевецкой. СКФУ, 2022. http://dx.doi.org/10.38006/9612-62-6.2022.196.198.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lethagen, S., A. S. Harris, and I. M. Nilsson. "A NEW DELIVERY SYSTEM FOR DDAVP: CLINICAL EXPERIENCE OF DDAVP SPRAY PUMP IN MILD HAEMOPHILIA A AND vWD TYPE I." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644704.

Full text
Abstract:
Until recently, the reliability and predectibility of the intranasal route of administration of DDAVP has been too poor to recommend it in routine practice.With the development of a new delivery system in the form of a spray puip we have previously shown that absorption and biological effect of DDAVP in volunteers is enhanced(1).In this patient study we conpared intranasal administration of 300 pg DDAVP using a newly developed pre-corrpression spray pinp with intravenous administration of 0.3 - 0.4 pg/kg. We studied 24 patients with mild haemophilia A, 23 with mild vWD Type IA and 8 with Type IB. We measured VIII:C (one-stage assay), vW:Ag (IRMA) and bleeding time (Simplate II) before and 30 - 60 min and 1 hour post treatment after i.v. and i.n. administration respectively.The spray resulted in a 2 to 4 times increase in basal levels of VIII:C and vW:Ag and was comparable in effect to intravenous administration. Moreover, bleeding time was significantly reduced to within the normal range in most patients. Several patients reported good clinical effects of the spray after tooth extraction, menorrhagia and epistaxis.We conclude that the DDAVP spray is a clear improvement over previous atterpts at intranasal administration. The spray deposits well controlled and reproducible doses in the nasal cavity resulting in a clear enhancement in absorption with a magnitude and reliability of its biological effect which is corparable to the intravenous delivery. Furthermore, the spray offers a convenient and practical means of self-treatment to haemophilia patients without delay.1. Harris A.S., Nilsson I.M., Wagier Z.-G., Alkner U. Intranasal Administration of Peptides: Nasal Deposition, Biological Response, and Absorption of Desmopressin. J Pharm Sci (in press, December 1986).
APA, Harvard, Vancouver, ISO, and other styles
5

Lethagen, S., A. S. Harris, and I. M. Nilsson. "COMPARISON OF TO BIOLOGICAL EFFECT, PHARMACOKINETICS AND REPRODUCIBILITY OF INTRANASAL AND INTRAVENOUS ADMINISTRATION OF DDAVP." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644705.

Full text
Abstract:
DDAVP has previously mostly been given by the parenteral route but the development of intranasal delivery has made it possible for the patients to treat themselves at home without delay. The effect of intranasal administration of DDAVP as drops using a rhinyle catheter or a pipette has been unpredictable. The development of a spray has improved the intranasal administration of DDAVP with well controlled doses and better absorption.In this study we conpared intranasal administration of 300 pg DDAVP by spray, with intravenous administration of 0.2, 0.3 and 0.4 pg DDAVP/kg in 10 healthy volunteers. We measured the effect on VIII:C, VIII:Ag and vW:Ag and also followed plasma levels of DDAVP before and 10' , 30' , 45' , 60' , 90' , 2 h, 4 h, 6 h and 8 h after administration.We also studied the reproducibility of the spray effect. 10 healthy volunteers were tested before and 1 h after the administration of 300 pg DDAVP intranasally by spray on 5 different occasions with an interval of at least 1 week between the tests.The highest response was obtained after 0.3 μg/kg i.v. The response to 0.4 μg/kg i.v. was less than 0.3 μg/kg indicating that maximum stimulation was reached with 0.3 μg/kg. The effect of spray approximates the 0.2 μg/kg response.The reproducibility of the effect of the spray dose on VIII:C was 25% (coefficient of variation) and 33% for the intra-individual and inter-individual variation respectively. This corrpares favourably with the inter-individual variation after intravenous administration of 0.2 pg/kg (30%), 0.3 μg/kg (22%) and 0.4 μg/kg (35%). It was of interest to note that the intra- and inter-individual variation of pre-treatment basal levels of VIII:C was 14% and 17% respectively.Intranasal DDAVP (300 μg) is as effective as 0.2 μg/kg intravenously and provides an accurate, reproducible and convenient alternative to parenteral administration.
APA, Harvard, Vancouver, ISO, and other styles
6

Sohn, Jung Ho, Joo Young Kim, yong won Lee, Jae Hyun Lee, and Jung Won Park. "Intranasal Administration Of Unmethylated CpG-Oligodeoxynucleotide Attenuates Cockroach Extract-induced Pulmonary Inflammation." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a5763.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Rautiola, Davin, and Ronald A. Siegel. "Nasal Spray Device for Administration of Two-Part Drug Formulations." In 2019 Design of Medical Devices Conference. American Society of Mechanical Engineers, 2019. http://dx.doi.org/10.1115/dmd2019-3216.

Full text
Abstract:
Intranasal drug delivery is an attractive route to noninvasively achieve a rapid therapeutic effect, avoid first pass metabolism, and bypass the blood brain barrier. However, the types of drugs that can be administered by this route has been limited, in part, by device technology. Herein, we describe a pneumatic nasal spray device that is capable of mixing liquid and solid components of a drug formulation as part of the actuation process during dose administration. The ability to store a nasal spray drug formulation as two separate components can be leveraged to solve a variety of stability issues that would otherwise preclude intranasal administration. Examples of drugs that could be delivered intranasally by utilizing this two-part formulation strategy include biomolecules that are unstable in solution and low solubility drugs that can be rendered into metastable supersaturated solutions. A proof of concept nasal spray device prototype was constructed to demonstrate that a liquid and solid can be rapidly mixed and atomized into a spray in a single action. The primary breakup distance and angle of the spray cone were measured as a function of the function of the propellant gas pressure.
APA, Harvard, Vancouver, ISO, and other styles
8

Fatianova, Alina, Valentina Lavrinenko, and Tatiana Kurliandchik. "NEUROHYPOPHYSIAL VASOPRESSIN HYDROOSMOTIC EFFECT REALIZATION IN THE RAT KIDNEY UNDER DOPAMINE ADMINISTRATION." In XVII INTERNATIONAL INTERDISCIPLINARY CONGRESS NEUROSCIENCE FOR MEDICINE AND PSYCHOLOGY. LCC MAKS Press, 2021. http://dx.doi.org/10.29003/m2363.sudak.ns2021-17/383.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Sidorov, Nikita Gennadievich, Natalia Alexandrovna Mikhailova, and Vladimir Vladimirovich Gureev. "STUDY OF THE ACUTE TOXICITY OF A NASAL SPRAY BASED ON ANTIGENS OF OPPORTUNISTIC BACTERIA." In Themed collection of papers from Foreign international scientific conference «Joint innovation - joint development». by HNRI «National development» in cooperation with PS of UA. February 2025. - Harbin (China). Crossref, 2025. https://doi.org/10.37539/250227.2025.63.15.011.

Full text
Abstract:
The article presents the results of determining the acute toxicity of a nasal spray based on antigens of opportunistic bacteria in two formulations: with and without a prolonging agent. According to the Hodge and Sterner toxicity classification, when administered to mice at the maximum possible doses, the formulations were classified as up to class 4 toxicity for subcutaneous administration and up to class 3 toxicity for intranasal administration. These findings support the feasibility of further development of the formulations.
APA, Harvard, Vancouver, ISO, and other styles
10

Quispe, Rodrigo, Jorge A. Trevino, Faizan Khan, and Vera Novak. "Strategies for nose-to-brain drug delivery." In the 8th International Workshop on Innovative Simulation for Healthcare. CAL-TEK srl, 2019. http://dx.doi.org/10.46354/i3m.2019.iwish.017.

Full text
Abstract:
"Intranasal drug administration is an effective method that has shown promise for delivering drugs directly to the brain. This approach is associated with many challenges, and efficacy in bypassing blood-brain barrier (BBB) is debated. This review describes the pathways of nose-to-brain drug delivery, physicochemical drug properties that influence drug uptake through the nasal epithelium, physiological barriers, methods to enhance nose-to-brain absorption, drug bioavailability and biodistribution, and intranasal devices for nose-to-brain drug delivery. The mechanism of each device is described and supporting evidence from clinical trials is presented. This paper summarizes strategies involved in nose-to-brain drug delivery and provides evidence of potential efficacy of nose-braindelivery from clinical trials."
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Intranasal administration of dopamine"

1

Chen, Qi, Ryan Vander Veen, Darin M. Madson, and D. L. Hank Harris. Immunization for Influenza A Virus by Intranasal Administration of Alphavirus Replicon Particles. Iowa State University, 2013. http://dx.doi.org/10.31274/ans_air-180814-29.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Singh, Ruchi, Akhiya Nail, and Nirendra Kumar Rai. Effectiveness of Vitamin B12 Supplementation on cognitive, motor & mood instability of Parkinson’s disease patients on levodopa treatment :A Systematic review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.2.0066.

Full text
Abstract:
Review question / Objective: The treatment of choice for patients of Parkinson's disease is levodopa. However, levodopa has been suggested to decrease Vit B12 level in these patients. Thus, the research question for this systematic review is whether vit B 12 supplementation in Parkinson's disease(PD) patients on treatment with levodopa improves vit B12 level effecting the Cognition, Motor functions and Mood instability among them in comparison to PD patients on levodopa treatment who are not supplemented with Vit B12. Condition being studied: Parkinson disease is the progressive degeneration of dopaminergic neurons present within the substantia nigra that can lead to altered movements along with the prevalence of cognitive and mood instability as a result of dopamine(neurotransmitter) deficiency. The most effective treatment for the Parkinson's disease is the administration of levodopa, a dopamine precursor . Long term treatment with levodopa causes an increase in homocysteine levels and tissue deficiency of vitamin B12 and folate may occur. Vitamin B12 supplementation is administered as after management regime, in Parkinson patient on levodopa treatment . This study aims to conduct a systematic review, of studies , randomized control trials investigating the ability of vitamin B12 supplementation to enhances the recovery/reduce the decline, if any, of the symptoms of cognitive, motor, mood impairments associated with Parkinson's disease patient on levodopa treatment.
APA, Harvard, Vancouver, ISO, and other styles
3

99mTc SPECT-CT, Consensus QIBA Profile. Chair Yuni Dewaraja and Robert Miyaoka. Radiological Society of North America (RSNA)/Quantitative Imaging Biomarkers Alliance (QIBA), 2019. https://doi.org/10.1148/qiba/20191021.

Full text
Abstract:
The quantification of 99mTc labeled biomarkers can add unique value in many different settings, ranging from clinical trials of investigation new drugs to the treatment of individual patients with marketed therapeutics. For example, goals of precision medicine include using companion radiopharmaceutical diagnostics as just-in-time, predictive biomarkers for selecting patients to receive targeted treatments, customizing doses of internally administered radiotherapeutics, and assessing responses to treatment. This Profile describes quantitative outcome measures that represent proxies of target concentration or target mass in topographically specific volumes of interest (VOIs). These outcome measures are usually expressed as the percent injected dose (i.e., radioactivity) per mL of tissue (%ID/mL), a standard uptake value ratio (SUVr), or a target-to-background ratio (TBR). In this profile, targeting is not limited to any single mechanism of action. Targeting can be based on interaction with a cell surface protein, an intracellular complex after diffusion, protein-mediated transport, endocytosis, or mechanical trapping in a capillary bed, as in the case of transarterial administration of embolic microspheres. Regardless, the profile focuses on quantification in well-defined volumes of interest. Technetium-99m based dopamine transporter imaging agents, such as TRODAT, are nearly direct links with some aspects of the predecessor profile on 123I-ioflupane for neurodegenerative disorders. (See www.qibawiki.rsna.org ) Cancer is often a base case of convenience for new material in this profile, but the intent is to create methods that can be useful in other therapeutic areas where the diseases are characterized by spatially-limited anatomical volumes, such as lung segments, or multifocal aggregations of targets, such as white blood cell surface receptors on pulmonary nodules in patients with sarcoidosis. Neoplastic masses that can be measured with x-ray computed tomography (CT) or magnetic resonance imaging (MRI) are the starting point. However, the intent is to create a profile that can be extrapolated to diseases in other therapeutic areas that are also associated with focal, or multi-focal pathology, such as pulmonary granulomatous diseases of autoimmune or infectious etiology, non-oncological diseases of organs such as polycystic kidney disease, and the like. The criteria for measurability are based on the current resolution of most SPECT-CT systems in clinical practice, and are independent of criteria for measurability in other contexts. For this SPECT profile, conformance requires that a “small” VOI must be greater than 30 mL to be measurable. It is understood that much smaller VOIs can sometimes exhibit high conspicuity on SPECT, but these use cases are beyond the scope of this profile and will not be tested for conformance in this version. It is left to individual stakeholders to show the extent to which they can achieve conformance when measuring VOIs less than 30 mL. The detection of smaller changes during clinical trials of large groups can be achieved by referring to the QIBA companion guidance on powering trials. The Claims (Section 2) asserts that compliance with the specifications described in this Profile will produce cross sectional estimates of the concentration of radioactivity [kBq/mL] in a volume of interest (VOI) or a target-to-background ratio (TBR) within a defined confidence interval (CI), and distinguish true biological change from system variance (i.e., measurement error) in individual patients or clinical trials of many patients who will be studied longitudinally with 99mTc SPECT agents. Both claims are founded on observations that target density varies between patients with the same disease as well as within patients with multi-focal disease. The Activities (Section 3) describes the requirements that are placed on the Actors who need to achieve the Claim. Section 3 specifies what the actors must do in order to estimate the amount of radioactivity in a volume of interest, expressed in kBq/mL (ideal) or as a TBR (acceptable) within a 95% CI surrounding the true value. Measurands such as %ID/mL are targets for nonclinical studies in animal models that use terminal sacrifice to establish ground truth for imaging studies. TBRs can be precarious, as the assumptions that depend on the physiology of the background regions matching the volume of interest can be hard to accept sometimes. It is up to each individual stakeholder to qualify the background regions used in their own use case. This profile qualifies only a few in some very limited contexts as examples. The Assessment Procedures (Section 4) for evaluating specific requirements are defined as needed. The requirements are focused on achieving sufficient accuracy and avoiding unnecessary variability of the measurements. The clinical performance target is to achieve a 95% confidence interval for concentration in units of kBq/mL (kilobequerels per milliliter) or %ID/mL (percent injected dose per milliliter) or TBR with both a reproducibility and a repeatability of +/- 8% within a single individual under zero-biological-change conditions. This document is intended to help clinicians basing decisions on these biomarkers, imaging staffs generating measurements of these biomarkers, vendors who are developing related products, purchasers of such products, and investigators designing trials. Note that this document only states requirements to achieve the claims, not “requirements on standard of care” nor compliance with any particular protocol for treating participants in clinical trial settings. Conformance to this Profile is secondary to properly caring for patients or adhering to the requirements of a protocol. QIBA Profiles addressing other imaging biomarkers using CT, MRI, PET and Ultrasound can be found at www.qibawiki.rsna.org.
APA, Harvard, Vancouver, ISO, and other styles
4

Oxytocin Administration, Neural Sensitivity, and Autism. ACAMH, 2023. http://dx.doi.org/10.13056/acamh.24918.

Full text
Abstract:
In this Papers Podcast, Dr. Mattijis Moerkerke discusses his JCPP paper 'Can repeated intranasal oxytocin administration affect reduced neural sensitivity towards expressive faces in autism? A randomized controlled trial'. Mattijis is the first author of the paper.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Intranasal administration of dopamine' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography